ArticleFrontiers in allergy2025
Multiplex IgE peanut panels: a critical appraisal of assay designs and the good, the bad, and the ugly features of the applied allergen components.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiplex allergy assays are currently well-established in allergy diagnostics. However, the different assays in terms of designs and performance are also claimed to be heterogeneous as no agreed standards and requirements are available. Objective: We aimed to compare the analytical assay designs of the ISAC, ALEX, and EUROLINE peanut (Ara h) panels and the features of the applied isoallergens and variants to create more awareness of the heterogeneity of multiplex allergy assays. Methods: We conducted a multi-source survey in publicly available data sources and among manufacturers and performed correlation studies using patients' serum samples. Results: The survey proved that the panels are indeed very heterogeneous in many ways, especially regarding the allergen component origin and isoallergen composition. Despite that, we found adequate correlations between IgE against the clinically relevant Ara h storage proteins measured by the panels. However, for the clinically relevant lipid transfer protein Ara h 9, the correlations were less adequate, which could be caused by the different Ara h 9 isoallergens used in the studied panels. For cross-reactive carbohydrate determinants (CCDs), the results were complicated, which also corresponds to the complex nature of CCDs and the different inhibition procedures. The detection of subpopulations of patients for all panallergens illustrated the heterogeneous nature of peanut IgE in general and of the peanut panels studied. Regarding the overall features provided for the three panels, we classified the peanut allergen components and CCDs by their good, bad, and even ugly features when used within these panels. Conclusions: Knowledge of the origin and respective isoallergen specifications of the peanut allergen components including the exact CCD composition is essential. Together with that of the variants, this should be documented more adequately in scientific studies and in the respective instructions for the use of multiplex allergy assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.